Compounding Governance as Enterprise Risk Management

In today’s healthcare environment, sterile compounding oversight can no longer be viewed solely as an operational responsibility housed within the pharmacy department. As regulatory scrutiny intensifies and patient safety expectations continue to rise, compounding governance must be elevated to a board-level enterprise risk management (ERM) function.

Organizations that adopt recognized frameworks such as COSO Enterprise Risk Management and ISO 31000 are increasingly recognizing that compounding risks extend far beyond compliance checklists. A single breakdown in sterile compounding practices can trigger a cascade of enterprise-wide consequences, affecting patient safety, organizational reputation, regulatory standing, and financial performance.

From an ERM perspective, sterile compounding risks map directly to core enterprise risk categories:

• Operational Risk: Process failures, environmental control lapses, supply chain disruptions, and workforce competency gaps.

• Regulatory Risk: Noncompliance with USP standards, accreditation requirements, and state or federal regulations.

• Reputational Risk: Public trust erosion following adverse events, inspection findings, or media scrutiny.

This broader view reframes compounding governance from a technical pharmacy function into a strategic organizational imperative. Boards and executive leadership teams should expect routine reporting on compounding risk indicators, mitigation strategies, and organizational preparedness, just as they do for cybersecurity, quality, and financial risks.

Equally important, this shift transforms the role of pharmacy leadership. Pharmacy executives are not merely managers of tasks, inspections, and policies; they are risk stewards responsible for identifying, assessing, mitigating, and communicating risks that could affect the entire enterprise. Their expertise becomes a critical component of organizational resilience and governance.

As healthcare systems mature their risk management practices, the most successful organizations will be those that recognize sterile compounding governance as more than a compliance obligation. It is a strategic safeguard for patient safety, institutional trust, and long-term organizational performance, a true enterprise risk management priority worthy of boardroom attention.

For healthcare leaders, the question is no longer whether sterile compounding is a pharmacy issue. The question is whether the organization is governing it as the enterprise risk it has become.